Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex.
Chu YY, Chen MK, Wei Y, Lee HH, Xia W, Wang YN, Yam C, Hsu JL, Wang HL, Chang WC, Yamaguchi H, Jiang Z, Liu C, Li CF, Nie L, Chan LC, Gao Y, Wang SC, Liu J, Westin SN, Lee S, Sood AK, Yang L, Hortobagyi GN, Yu D, Hung MC.
Chu YY, et al. Among authors: wei y.
Nat Cancer. 2022 Oct;3(10):1211-1227. doi: 10.1038/s43018-022-00438-2. Epub 2022 Oct 17.
Nat Cancer. 2022.
PMID: 36253486
Free PMC article.